RayzeBio is seeking an Associate Director, In-Vivo Pharmacology to provide scientific and operational leadership across oncology programs with a focus on radiopharmaceutical therapeutics (RPTs). This role provides functional leadership to senior scientists to design and execute high-quality in-vivo studies that inform program strategy from discovery through IND-enabling development.
The Associate Director will set direction, ensure alignment, and drive high-quality decision-making, while maintaining accountability for vivarium operations, animal welfare, and regulatory compliance (IACUC/AALAC). This is a highly cross-functional role that operates close to the science without serving as the primary experimentalist. The ideal candidate combines deep expertise in oncology in-vivo pharmacology with a strong sense of ownership, practical decision-making, and comfort operating at the intersection of science, operations, and compliance in a fast-moving biotech environment.
Key Responsibilities- Lead the in-vivo pharmacology strategy for oncology RPT programs by supporting scientists in study design, execution, data interpretation, and translational relevance.
- Serve as a scientific thought partner, providing feedback and direction on: model selection (CDX/PDX), dose and schedule rationale and endpoint definition and evaluability. Support selection of mouse strains, tumor models, activity levels, and fractionation schemes appropriate for Lu-177, Ac-225, and future RPT isotopes and modalities.
- Ensure consistency, rigor, and strategic alignment across in-vivo studies supporting multiple programs from early discovery through IND-enabling development.
- Own efficacy and biodistribution strategy for radiopharmaceutical programs, incorporating tumor growth kinetics, delayed response patterns, and modality-specific considerations. Ensure study designs reflect radiobiological realities.
- Partner closely with dosimetry/physics, imaging, radiochemistry, biology and DMPK teams to align in-vivo studies with absorbed dose and exposure-response understanding.
- Review and contribute to in-vivo pharmacology sections of study reports and IND-enabling regulatory submissions.
- Serve as a point of escalation for animal care, biosecurity, or facility-related issues impacting studies and operations.
Education and Experience- Ph.D. in Pharmacology, Cancer Biology, Toxicology, or related field, with 8+ years of relevant industry experience
- Strong track record in in-vivo oncology pharmacology, including xenograft efficacy studies and supporting preclinical programs advancing toward IND
- Demonstrated ability to lead complex, cross-functional teams/efforts and make pragmatic decisions in a fast-paced R&D environment
- Working knowledge of IACUC processes, animal welfare regulations and experience supporting AALAC accreditation activities
- Experience applying AI and computational tools to enhance data analysis, automate routine workflows, and support data-driven decision-making is desirable
- Experience with radiopharmaceuticals, radioligand therapies, or radiation-based modalities including familiarity with biodistribution, dosimetry, and radiation biology concepts preferred
If you come across a role that intrigues you but doesn't perfectly line up with your resume, we encourage you to apply anyway. You could be one step away from work that will transform your life and career.
Compensation Overview:San Diego - RayzeBio - CA: $190,539 - $230,888
The starting compensation range(s) for this role are listed above for a full-time employee (FTE) basis. Additional incentive cash and stock opportunities (based on eligibility) may be available. The starting pay rate takes into account characteristics of the job, such as required skills, where the job is performed, the employee's work schedule, job-related knowledge, and experience. Final, individual compensation will be decided based on demonstrated experience.
Eligibility for specific benefits listed on our careers site may vary based on the job and location. For more on benefits, please visit https://careers.bms.com/life-at-bms/.
Benefit offerings are subject to the terms and conditions of the applicable plans in effect at the time and may require enrollment. Our benefits include:
- Health Coverage: Medical, pharmacy, dental, and vision care.
- Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
- Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.
Work-life benefits include:Paid Time Off
- US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
- Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
Based on eligibility*, additional time off for employees may include unlimited paid sick time, up to 2 paid volunteer days per year, summer hours flexibility, leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs and an annual Global Shutdown between Christmas and New Years Day.
All global employees full and part-time who are actively employed at and paid directly by BMS at the end of the calendar year are eligible to take advantage of the Global Shutdown.
*Eligibility Disclosure: The summer hours program is for United States (U.S.) office-based employees due to the unique nature of their work. Summer hours are generally not available for field sales and manufacturing operations and may also be limited for the capability centers. Employees in remote-by-design or lab-based roles may be eligible for summer hours, depending on the nature of their work, and should discuss eligibility with their manager. Employees covered under a collective bargaining agreement should consult that document to determine if they are eligible. Contractors, leased workers and other service providers are not eligible to participate in the program.
RayzeBio and Bristol Myers SquibbRayzeBio was acquired by Bristol Myers Squibb (BMS) in 2024 and is a wholly-owned subsidiary of BMS; however, RayzeBio will continue to operate as a standalone organization.
